Who is sponsoring NCT00003647?

NCT00003647 is sponsored by Vical.

What condition does NCT00003647 study?

NCT00003647 studies Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma.

What drugs are being tested in NCT00003647?

Interventions: allovectin-7, allovectin-7/dacarbazine, dacarbazine.

What is the status of NCT00003647?

NCT00003647 is currently COMPLETED.

Last reviewed 2008-07-23 · How we verify

Phase III Randomized Study of Dacarbazine With or Without Allovectin-7 in Patients With Metastatic Melanoma

NCT00003647 Phase 3 COMPLETED

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of dacarbazine with or without immunotherapy in treating patients who have stage III or stage IV melanoma.

Details

Lead sponsor	Vical
Phase	Phase 3
Status	COMPLETED
Start date	1998-07
Completion	2002-09

Conditions

Stage IV Melanoma
Stage III Melanoma
Recurrent Melanoma

Interventions

allovectin-7
allovectin-7/dacarbazine
dacarbazine

Countries

United States